HC Advisors’s Eli Lilly LLY Stock Holding History

HC Advisors’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,504	Closed	-$3.5M	–	66
2024 Q1	$3.5M	Hold	4,504	–	–	1.67%	15
2023 Q4	$2.63M	Hold	4,504	–	–	1.47%	17
2023 Q3	$2.42M	Sell	4,504 -100	-2%	-$51.5K	1.44%	18
2023 Q2	$2.16M	Sell	4,604 -109	-2%	-$45.7K	1.25%	21
2023 Q1	$1.62M	Buy	4,713 +109	+2%	+$36.8K	1%	24
2022 Q4	$1.68M	Buy	4,604 +100	+2%	+$35.5K	1.15%	21
2022 Q3	$1.46M	Hold	4,504	–	–	1%	25
2022 Q2	$1.46M	Sell	4,504 -363	-7%	-$109K	1.04%	24
2022 Q1	$1.39M	Hold	4,867	–	–	0.88%	30
2021 Q4	$1.34M	Buy	4,867 +4	+0.1%	+$1.01K	0.82%	27
2021 Q3	$1.12M	Buy	4,863 +1,595	+49%	+$394K	0.74%	26
2021 Q2	$750K	Buy	+3,268	New	+$656K	0.46%	35
2020 Q3	–	Sell	-9,403	Closed	-$1.54M	–	82
2020 Q2	$1.54M	Buy	+9,403	New	+$1.44M	1.28%	19
2020 Q1	–	Sell	-9,638	Closed	-$1.27M	–	45
2019 Q4	$1.27M	Buy	+9,638	New	+$1.12M	1.31%	21

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HC Advisors's LLY Position: Q2 2024 in Review

HC Advisors sold out of Eli Lilly (LLY) in Q2 2024, closing a stake of 4,504 shares — an estimated $3.5M sold.

HC Advisors first reported a position in LLY in Q4 2019 and held it in 14 quarters. The position peaked at $3.5M in Q1 2024. 3,564 funds tracked by Wall St. Rank hold LLY as of Q2 2024.

HC Advisors reported no remaining Eli Lilly position as of Q2 2024 after selling out during the quarter.
HC Advisors sold 4,504 Eli Lilly shares in Q2 2024, an estimated $3.5M.
HC Advisors first reported a position in Eli Lilly in Q4 2019 and held it in 14 quarters.
HC Advisors's Eli Lilly position peaked at $3.5M in Q1 2024.
3,564 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2024.

Based on HC Advisors's 13F filing for Q2 2024, filed 7 Aug 2024.